BACKGROUND: Sapropterin dihydrochloride, an EMEA-approved synthetic formulation of BH4, has been available in Europe since 2009 for PKU patients older than 4 years, but its use with younger children is allowed in France based on an expert recommendation. We report the cases of 15 patients treated under the age of 4 years and demonstrate the safety and efficacy of this treatment for patients in this age group. PATIENTS AND METHOD: We report the use of BH4 in 15 PKU patients treated before the age of 4 years. RESULTS: Fifteen patients were enrolled in this retrospective study. Mean phenylalaninemia at diagnosis was 542 ± 164 μM and all patients had mild PKU (maximal phenylalaninemia: 600-1200 μM). BH4 responsiveness was assessed using a 24-hour BH4 loading test (20 mg/kg), performed during the neonatal period (n = 11) or before 18 months of age (n = 4). During the test, these patients exhibited an 80 ± 12% decrease in phenylalaninemia. Long-term BH4 therapy was initiated during the neonatal period (n = 7) or at the age of 13 ± 12 months (n = 8). The median duration of treatment was 23 months [min 7; max 80]. BH4 therapy drastically improved dietary phenylalanine tolerance (456 ± 181 vs 1683 ± 627 mg/day, p < 0.0001) and allowed a phenylalanine-free amino acid mixture to be discontinued or not introduced in 14 patients. Additionally, in the eight patients treated after a few months of diet therapy, BH4 treatment significantly decreased mean phenylalaninemia (352 ± 85 vs 254 ± 64 μM, p < 0.05), raised the percentage of phenylalaninemia tests within therapeutic targets [120-300 μM] (35 ± 25 vs 64 ± 16%, p < 0.05), and reduced phenylalaninemia variance (130 ± 21 vs 93 ± 27 μM, p < 0.05). No side effects were reported. CONCLUSION: BH4-therapy is efficient and safe before the age of 4 years in mild PKU, BH4-responsive patients.
BACKGROUND:Sapropterin dihydrochloride, an EMEA-approved synthetic formulation of BH4, has been available in Europe since 2009 for PKUpatients older than 4 years, but its use with younger children is allowed in France based on an expert recommendation. We report the cases of 15 patients treated under the age of 4 years and demonstrate the safety and efficacy of this treatment for patients in this age group. PATIENTS AND METHOD: We report the use of BH4 in 15 PKUpatients treated before the age of 4 years. RESULTS: Fifteen patients were enrolled in this retrospective study. Mean phenylalaninemia at diagnosis was 542 ± 164 μM and all patients had mild PKU (maximal phenylalaninemia: 600-1200 μM). BH4 responsiveness was assessed using a 24-hour BH4 loading test (20 mg/kg), performed during the neonatal period (n = 11) or before 18 months of age (n = 4). During the test, these patients exhibited an 80 ± 12% decrease in phenylalaninemia. Long-term BH4 therapy was initiated during the neonatal period (n = 7) or at the age of 13 ± 12 months (n = 8). The median duration of treatment was 23 months [min 7; max 80]. BH4 therapy drastically improved dietary phenylalanine tolerance (456 ± 181 vs 1683 ± 627 mg/day, p < 0.0001) and allowed a phenylalanine-free amino acid mixture to be discontinued or not introduced in 14 patients. Additionally, in the eight patients treated after a few months of diet therapy, BH4 treatment significantly decreased mean phenylalaninemia (352 ± 85 vs 254 ± 64 μM, p < 0.05), raised the percentage of phenylalaninemia tests within therapeutic targets [120-300 μM] (35 ± 25 vs 64 ± 16%, p < 0.05), and reduced phenylalaninemia variance (130 ± 21 vs 93 ± 27 μM, p < 0.05). No side effects were reported. CONCLUSION:BH4-therapy is efficient and safe before the age of 4 years in mild PKU, BH4-responsive patients.
Authors: Rosa Gassió; Rafael Artuch; Maria Antonia Vilaseca; Eugenia Fusté; Cristina Boix; Anna Sans; Jaume Campistol Journal: Dev Med Child Neurol Date: 2005-07 Impact factor: 5.449
Authors: Piotr Adamczyk; Aurelia Morawiec-Knysak; Paweł Płudowski; Beata Banaszak; Jacek Karpe; Wojciech Pluskiewicz Journal: J Bone Miner Metab Date: 2010-08-13 Impact factor: 2.626
Authors: François Feillet; Céline Chery; Fares Namour; Antoine Kimmoun; Elisabeth Favre; Elisabeth Lorentz; Shyue-Fang Battaglia-Hsu; Jean-Louis Guéant Journal: Early Hum Dev Date: 2008-03-05 Impact factor: 2.079
Authors: Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho Journal: Metab Brain Dis Date: 2013-05-09 Impact factor: 3.584
Authors: Luis Aldámiz-Echevarría; Marta Llarena; María A Bueno; Jaime Dalmau; Isidro Vitoria; Ana Fernández-Marmiesse; Fernando Andrade; Javier Blasco; Carlos Alcalde; David Gil; María C García; Domingo González-Lamuño; Mónica Ruiz; María A Ruiz; Luis Peña-Quintana; David González; Felix Sánchez-Valverde; Lourdes R Desviat; Belen Pérez; María L Couce Journal: J Hum Genet Date: 2016-04-28 Impact factor: 3.172
Authors: Anna Dikalova; Judy L Aschner; Mark R Kaplowitz; Marshall Summar; Candice D Fike Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-08-19 Impact factor: 5.464
Authors: A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen Journal: Orphanet J Rare Dis Date: 2017-10-12 Impact factor: 4.123
Authors: Nicola Longo; Komudi Siriwardena; Annette Feigenbaum; David Dimmock; Barbara K Burton; Sylvia Stockler; Susan Waisbren; William Lang; Elaina Jurecki; Charlie Zhang; Suyash Prasad Journal: Genet Med Date: 2014-09-18 Impact factor: 8.822
Authors: Karen Anjema; Margreet van Rijn; Floris C Hofstede; Annet M Bosch; Carla E M Hollak; Estela Rubio-Gozalbo; Maaike C de Vries; Mirian C H Janssen; Carolien C A Boelen; Johannes G M Burgerhof; Nenad Blau; M Rebecca Heiner-Fokkema; Francjan J van Spronsen Journal: Orphanet J Rare Dis Date: 2013-07-10 Impact factor: 4.123
Authors: Karen Anjema; Floris C Hofstede; Annet M Bosch; M Estela Rubio-Gozalbo; Maaike C de Vries; Carolien C A Boelen; Margreet van Rijn; Francjan J van Spronsen Journal: Orphanet J Rare Dis Date: 2016-01-29 Impact factor: 4.123